Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Anna Pavlick, MD
Advertisement
Articles by Anna Pavlick, MD
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.
Advertisement
Latest Updated Articles
Dr. Anna Pavlick on Options for First-Line Therapy in Late-Stage MelanomaPublished: June 13th 2019 | Updated:
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in RemissionPublished: June 20th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
SABCS 2025: The Top 5 Takeaways for Breast Cancer Research
2
Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma
3
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
4
RAD51 Test May Improve Patient Selection of Olaparib in BRCA1/2 or PALB2 HER2– Breast Cancer
5